QuiaPEG Pharmaceuticals Holding AB Share Price

Equities

QUIA

SE0020678159

Pharmaceuticals

End-of-day quote Nasdaq Stockholm 03:30:00 20/06/2024 am IST 5-day change 1st Jan Change
0.069 SEK -4.43% Intraday chart for QuiaPEG Pharmaceuticals Holding AB -25.49% +4.39%

Financials

Sales 2022 55.74L 5L 4.43Cr Sales 2023 43.74L 4L 3.48Cr Capitalization 27.29L 3L 2.17Cr
Net income 2022 -2Cr -19.04L -16Cr Net income 2023 -1.6Cr -15.24L -13Cr EV / Sales 2022 7.85 x
Net Debt 2022 1.3Cr 12.34L 10Cr Net Debt 2023 2.05Cr 19.53L 16Cr EV / Sales 2023 5.31 x
P/E ratio 2022
-1.15 x
P/E ratio 2023
-1.97 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 66.36%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.43%
1 week-25.49%
Current month-8.00%
1 month+2.99%
3 months+38.00%
6 months-9.09%
Current year+4.39%
More quotes
1 week
0.05
Extreme 0.0501
0.15
1 month
0.05
Extreme 0.0501
0.15
Current year
0.05
Extreme 0.0463
0.15
1 year
0.03
Extreme 0.0261
1.58
3 years
0.03
Extreme 0.0261
117.50
5 years
0.03
Extreme 0.0261
326.00
10 years
0.03
Extreme 0.0261
570.00
More quotes
Date Price Change Volume
20/24/20 0.069 -4.43% 7,188,867
19/24/19 0.0722 +15.34% 33,774,220
18/24/18 0.0626 -14.13% 1,598,363
17/24/17 0.0729 -21.27% 4,839,903
14/24/14 0.0926 +5.23% 1,635,876

End-of-day quote Nasdaq Stockholm, June 20, 2024

More quotes
QuiaPEG Pharmaceuticals Holding AB is a Sweden-based biotechnology company. The Company develops improved versions of clinically validated biopharmaceutical drugs based on PEGylation technology platform. The Company’s technology is applicable on proteins, peptides and small molecules and offers a half-life extension platform consisting of covalent, as well as extended release PEGylation. The Company focuses on development of long-acting biopharmaceuticals for the treatment of metabolic disorders. The main project intends to reduce the frequent injection therapy by requiring significantly fewer injections. The Company offers out-licensing and partnering opportunities. It has a patent portfolio with patents pending and an approved the United States patent covering chemical linkers.
Calendar
More about the company